Compare · NBIX vs NERV
NBIX vs NERV
Side-by-side comparison of Neurocrine Biosciences Inc. (NBIX) and Minerva Neurosciences Inc (NERV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. NBIX focuses on Biotechnology: Biological Products (No Diagnostic Substances), while NERV focuses on Biotechnology: Pharmaceutical Preparations.
- NBIX is the larger of the two at $16.79B, about 156.0x NERV ($107.6M).
- NBIX has been more active in the news (11 items in the past 4 weeks vs 9 for NERV).
- NBIX has more recent analyst coverage (25 ratings vs 3 for NERV).
- Company
- Neurocrine Biosciences Inc.
- Minerva Neurosciences Inc
- Price
- -
- -
- Market cap
- $16.79B
- $107.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1996
- 2014
- News (4w)
- 11
- 9
- Recent ratings
- 25
- 3
Neurocrine Biosciences Inc.
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Latest NBIX
- Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
- Chief Medical Officer Roberts Eiry was granted 8,314 stock options and was granted 1,506 restricted stock units (SEC Form 4)
- Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
- Director Morrow George J exercised 15,000 shares at a strike of $53.64 and sold $2,335,982 worth of shares (15,000 units at $155.73) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Gano Kyle converted options into 614 shares and covered exercise/tax liability with 332 shares, increasing direct ownership by 0.18% to 155,010 units (SEC Form 4) to satisfy withholding obligation
- Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
- Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- SEC Form 10-Q filed by Neurocrine Biosciences Inc.
- Neurocrine Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
Latest NERV
- Minerva Neurosciences Inc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences Inc
- Amendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences Inc
- SEC Form 10-Q filed by Minerva Neurosciences Inc
- Minerva Neurosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates
- Director Kaul Inderjit was granted 2,328 stock options (SEC Form 4)
- Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
- Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
- Minerva Neurosciences to Participate in Two Upcoming Investor Conferences